**Contemporary Management in Metastatic Renal Cell Carcinoma**

#### Murat Lekili

*Celal Bayar University, Medical Faculty, Urology Department, Manisa Turkey* 

#### **1. Introduction**

360 Emerging Research and Treatments in Renal Cell Carcinoma

Syrjänen K and Hjelt L (1978). Grading of human renal adenocarcinoma. Scand J Urol

Tan X et al. (2008). Global analysis of metastasis-associated gene expression in primary

Thoenes W et al. (1986). Histopathology and classification of renal cell tumors (adenomas,

Uchida T et al. (2002). Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell

Usubutyn A et al. (1998). Comparison of grading systems for estimating the prognosis of

van Houwelingen KP et al. (2005). Prevalence of von Hippel-Lindau gene mutations in

Yang JC et al. (2007). Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic

Yang JC et al. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (5): 427-434. Yildiz E et al. (2004). Prognostic value of the expression of Ki-67, CD44 and vascular

Yoshimura R et al. (2004). Study of cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med

Zhang D et al. (1997). Vitamin E inhibits apoptosis, DNA modification, and cancer incidence

Zigeuner R et al. (2004). Value of p53 as a prognostic marker in histologic subtypes of renal

Zisman A et al. (2001). Re-evaluation of the 1997 TNM classification for RCC: T1 and T2 cut-

Zisman A et al. (2002). Mathematical model to predict individual survival for patients with

renal cell carcinoma. J Clin Oncol 20: 1368-1374.

sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC

renal cell cancer associated with enteritis and hypophysitis. J Immunother 30 (8):

endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU

induced by iron-mediated peroxidation in Wistar rat kidney. Cancer Res 57 (12):

cell carcinoma: a sytematic analysis of primary and metastatic tumor tissue.

off point at 4.5 cm rather than 7 cm better correlates with clinical outcome. J Urol

elements and their use for diagnostics. Pathol Res Pract 181: 125-143. Tsui KH et al. (2000). Prognostic indicators for renal cell carcinoma. A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163: 1090-1095. Tsujii M and DuBois RN (1995). Alterations in cellular adehesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501. Tuna B et al. (2004). Significance of COX-2 expression in human renal cell carcinoma.

cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer 123

oncocytomas and carcinomas). The basic cytological and histomorphological

Nephrol 12 (1): 49-55.

Urology 2004, 64(6):1116-1120.

carcinoma. Urology: 59: 615-620.

renal cell carcinoma. Int. Urol. Nephrol. 30:391-397.

(5): 1080-1088.

Cancer 5:57.

Int 93: 1087-1093.

Urology 63: 651-655.

13 (2): 229-233.

2410-2414.

166: 54-58.

825-830.

In addition to advancing our understanding of RCC, improved abdominal imaging technology has caused a migration of tumor stage and alteration of surgical strategies, with tumors commonly being diagnosed at an earlier stage. Despite these advances, the prognosis for patients with metastatic RCC is poor. Of the total number of patients with renal cancer, approximately a third either presents with or later develops metastatic disease. Unfortunately, for these patients, contemporary systemic therapies are generally ineffective—median survival is less than 1 year. Despite adjuvant systemic chemotherapy, hormonal or cytokine therapies, used alone or in combination, overall response rates rarely exceed 20% and durable, complete responses are rare. Targeted therapy in the management of metastatic renal cell cancer is newly introduced to urology practise. These drugs were used in very limited number of patients and only for clear cell histology. No recommendation to use these drugs for other than clear cell histology was seen in the literature. Nevertheless, there is a encouraging responses in trials with limited number of patients in the literature. Future advances are expected.

Spontaneous remissions in 0.8–7.0% of patients are reported in surgical series of clinical trials with previous surgical intervention. The role of surgical intervention in patients with metastatic renal cancer can be twofold. First, to render a patient clinically free of all sites of metastases ('metastasectomy'). Second, to resect the primary tumor prior to initiation of systemic therapy ('cytoreductive nephrectomy').

Studies that examine combinations of surgery and systemic therapy aim to improve survival in this high-risk group. In an attempt to address this important clinical issue, two randomized, prospective clinical trials were organized in the US (Southwest Oncology Group [SWOG]) and Europe (European Organization for Research and Treatment of Cancer [EORTC]) under similar entry criteria. The trials compared treatment of metastatic renal cancer with cytoreductive nephrectomy plus IFN-2b versus IFN-2b alone. Median survival of patients that underwent cytoreductive nephrectomy plus IFN-2b was significantly greater than that of those treated with IFN-2b only.

More recent metastasectomy studies also identified favorable clinical and surgical characteristics that were associated with a positive enhancement of outcome, but metastasectomy has never been assessed in a randomized clinical trial. It is not certain that

Contemporary Management in Metastatic Renal Cell Carcinoma 363

literature. The surgery time is longer, but postoperative analgesic requirements and hospital stay are decreasing. Therefore patients can take systemic therapy earlier than open surgery (Mean 35 vs 67 day). Patients without immunotherapy in case of disease progression are 13-77 % in literature (16). The shared conclusion of all the reports in literature is that the patients for cytoreductive nephrectomy have to be selected and they

The last clues for nephrectomy are quality of life. Hematuri, pain and paraneoplastic syndromes including anemia, anorexia, hypertension, hypocalcaemia etc. can be controlled

In conclusion, multidisciplinary approach including surgery stands in the forefront. But some questions are on the agenda. Timing and coordination. Which one should be the first,

For a long time, if possible excision of metastases is recommended. Complete metastasectomy was performed in Kierney" report. 59% and 31% 3 and 5 years survival was obtained in 77 patients with metastatic RCC. These survivals were significantly different from patients within conservative follow (20,21). In another retrospective study with 278

have to be in good ECOG performance status.

with nephrectomy.

O: Observation N: Nephrectomy

Fig. 1. SWOG and EORTC trials

**3. Metastasectomy** 

nephrectomy or systemic therapy?

metastasectomy can be curative, but operative intervention can provide effective palliation for symptomatic metastases in sites such as bone, the brain, and the adrenal gland. Ultimately a prospective clinical trial comparing metastasectomy to best standard systemic therapy will define the exact role of this approach.The occasionally unpredictable natural history of renal cancer and varying patient selection criteria can make the interpretation of outcomes from different centers difficult. As a conclusion although there is a tendency in favor of surgery, operative intervention for metastatic renal cancer is still controversial.

The aim of this review is more recent management modalities in the management of metastatic renal cell carcinoma. In addition, the role of surgery in metastatic RCC have been emphasised.

#### **2. The role of nephrectomy**

Although it is a part of multidisciplinary approach in the management of metastatic renal cell carcinoma (RCC), the role of Cytoreducive nephrectomy is still controversial in urologic literature. Recently according to some multicentric prospective randomized trials, because of providence little survival advantage, cytoreductive nephrectomy has gained some popularity. The objectives of nephrectomy in metastatic disease are avoidance of local symptoms and negative effects of primary tumor on immunological system (asynergy) and obtaining suitable nominee for immunotherapy, increasing patient quality of life and probably increased response to systemic therapy and finally increased overall survival. On the other hand, to prevent new metastases from primary tumor, capture of circulating immune cells, especially lymphocytes, which absorbed from primary tumor and so properties of immune pressure of primary tumor on immune system. Decreasing tumor burden may help the effectiveness of systemic therapy on tumor.

Surgical mortality rates are reported as 2-11%. In NCI trial, 62% patients can take immunotherapy and response rate is 18% in 195 patients. In this trial 38% patients cannot take immunotherapy because of complications of nephrectomy or rapid deterioration in general performance after progression of the disease (6). Some oncological centers recommend primary immunotherapy in order to avoid surgical morbidity especially in patients with clinical regression in metastatic sites (7,8).

Actually, two points provide that nephrectomy is a safe procedure; one is observation of spontaneous regression phenomena in metastatic sites after nephrectomy which is very rare. Freed has reported that 51 patients presented spontaneous regression after nephrectomy in literature (9). Similarly, NCI reported 4 patients (4.4%) have demonstrated spontaneous regression in 99 patients (10). In these 4 patients have only lung metastases and they were in remission for mean 24.3 months. Although spontaneous remission rates are very low, it is still very objective data in favor of nephrectomy. The other point for nephrectomy is unresponsiveness of primary tumor to systemic therapy. Radical nephrectomy may help to increase objective responses to systemic therapy. It has been obtained 32% objective response with immunotherapy after nephrectomy in 55 patients, but 4.7% response rate has been observed with same immunotherapeutic regimen in insitu tumor (11). Recently, surgical technique for cytoreductive nephrectomy is getting importance. Minimal invasive techniques gain popularity. While laparoscopic experience increased, laparoscopic radical nephrectomy performance is increasing in

metastasectomy can be curative, but operative intervention can provide effective palliation for symptomatic metastases in sites such as bone, the brain, and the adrenal gland. Ultimately a prospective clinical trial comparing metastasectomy to best standard systemic therapy will define the exact role of this approach.The occasionally unpredictable natural history of renal cancer and varying patient selection criteria can make the interpretation of outcomes from different centers difficult. As a conclusion although there is a tendency in favor of surgery, operative intervention for metastatic renal cancer is still controversial.

The aim of this review is more recent management modalities in the management of metastatic renal cell carcinoma. In addition, the role of surgery in metastatic RCC have been

Although it is a part of multidisciplinary approach in the management of metastatic renal cell carcinoma (RCC), the role of Cytoreducive nephrectomy is still controversial in urologic literature. Recently according to some multicentric prospective randomized trials, because of providence little survival advantage, cytoreductive nephrectomy has gained some popularity. The objectives of nephrectomy in metastatic disease are avoidance of local symptoms and negative effects of primary tumor on immunological system (asynergy) and obtaining suitable nominee for immunotherapy, increasing patient quality of life and probably increased response to systemic therapy and finally increased overall survival. On the other hand, to prevent new metastases from primary tumor, capture of circulating immune cells, especially lymphocytes, which absorbed from primary tumor and so properties of immune pressure of primary tumor on immune system. Decreasing tumor

Surgical mortality rates are reported as 2-11%. In NCI trial, 62% patients can take immunotherapy and response rate is 18% in 195 patients. In this trial 38% patients cannot take immunotherapy because of complications of nephrectomy or rapid deterioration in general performance after progression of the disease (6). Some oncological centers recommend primary immunotherapy in order to avoid surgical morbidity especially in

Actually, two points provide that nephrectomy is a safe procedure; one is observation of spontaneous regression phenomena in metastatic sites after nephrectomy which is very rare. Freed has reported that 51 patients presented spontaneous regression after nephrectomy in literature (9). Similarly, NCI reported 4 patients (4.4%) have demonstrated spontaneous regression in 99 patients (10). In these 4 patients have only lung metastases and they were in remission for mean 24.3 months. Although spontaneous remission rates are very low, it is still very objective data in favor of nephrectomy. The other point for nephrectomy is unresponsiveness of primary tumor to systemic therapy. Radical nephrectomy may help to increase objective responses to systemic therapy. It has been obtained 32% objective response with immunotherapy after nephrectomy in 55 patients, but 4.7% response rate has been observed with same immunotherapeutic regimen in insitu tumor (11). Recently, surgical technique for cytoreductive nephrectomy is getting importance. Minimal invasive techniques gain popularity. While laparoscopic experience increased, laparoscopic radical nephrectomy performance is increasing in

burden may help the effectiveness of systemic therapy on tumor.

patients with clinical regression in metastatic sites (7,8).

emphasised.

**2. The role of nephrectomy** 

literature. The surgery time is longer, but postoperative analgesic requirements and hospital stay are decreasing. Therefore patients can take systemic therapy earlier than open surgery (Mean 35 vs 67 day). Patients without immunotherapy in case of disease progression are 13-77 % in literature (16). The shared conclusion of all the reports in literature is that the patients for cytoreductive nephrectomy have to be selected and they have to be in good ECOG performance status.

The last clues for nephrectomy are quality of life. Hematuri, pain and paraneoplastic syndromes including anemia, anorexia, hypertension, hypocalcaemia etc. can be controlled with nephrectomy.

In conclusion, multidisciplinary approach including surgery stands in the forefront. But some questions are on the agenda. Timing and coordination. Which one should be the first, nephrectomy or systemic therapy?

#### **3. Metastasectomy**

For a long time, if possible excision of metastases is recommended. Complete metastasectomy was performed in Kierney" report. 59% and 31% 3 and 5 years survival was obtained in 77 patients with metastatic RCC. These survivals were significantly different from patients within conservative follow (20,21). In another retrospective study with 278

Contemporary Management in Metastatic Renal Cell Carcinoma 365

IFN-alpha is approved for the management of metastatic RCC in Europe and it is used routinely in Urological practise. Response rates are 10-25%. Recently, with recombinant forms response rates are increased to 29%. Survival advantage is 3-5 months. Toxicities are flu-like syndromes, dryness in skin and mucosal membranes, mental changes and depression. Combination with IL-2 is frequently applied in many centers. Dosage scheme is

A group of cytocine which are activated and regulated lymphocite growing and/ or

It is produced by activated CD4+ lymphocites.Cytotoxic T cells are stimulated by IL-2. CD8+ T cells, monocytes, lymphocyte activated killer lymphocytes (LAK) are activated and tumor necrosis factor is secreted. It is reported that IL-2 is as effective as 15% in many series.

Recently, there are more than 10 interleukin described other than IL-2 (IL-4; IL-7; IL-12 have

Phase 1 and 2 studies showed that response rates were 6-30%. Retrospective series showed that 15% and 20% response rates, but these results are not statistically significant.

Since more new agents have been produced and limited number of prospective, randomized, placebo-controlled studies have been reported, Therefore, we have evaluated

**4.3 Interferon** 

controversial.

differantiation

İnhalation

Synergy

only;

**4.4 Interleukin-2 (IL-2)** 

First described one is IL-2.

Rekombinant IL-2 (rIL-2)

Response rate 7-27%

been still investigating)

Mean 22% response

**4.6 Targeted therapies** 

1. Sorafenib (Nexavar®) 2. Sunitinib (Sutent®)

3. Bevasizumab (Avastin®) + IFN-alfa

Bolus high-dose *i.v.* infusion= highly toxic

Class I MHC Ag expression + T-lymphocite activation

Similar response rate as seen in high-dose IL-2

Nevertheless, mean survival is a little bit meaningful (9.1 vs 13 mos).

Only clear cell type is respondable

**4.5 Cytokine combination therapy** 

IFN-beta and gamma are ineffective.

patients, complete and incomplete metastasis resection can provide 44% vs 14% 5-years survival advantage (22).

In conclusion, the presence of solitary metastases and localization are important factors for clinical improvement. Resection of solitary metastases is recommended for survival and also quality of life.

#### **4. Systemic treatments**

#### **4.1 Cytotoxic drugs**

Standard cytotoxic drugs are generally ineffective. Response rates were reported below 10%. Response rate was reported 17% with Gemcitabine and 5-Florourasil combination in phase II study. Gemcitabine and capecitabine combination is effective as 20%. But grade 3-4 toxicity was reported. Same regimen reported by CALGB, Survival was 12% and stable disease rate was 59% in this study. Nevertheless toxicity was always a problem. 36% of patients could not continue the treatment protocol. The main problem is neutropenie and hand-food syndrome. Therefore, phase III studies can not be conducted.

#### **4.2 Immunotherapy**

Standard theurepathic regimen is still lack in the management of metastatic RCC. But interferon and interleukin therapy is in management list in many centers. Histological type is the most important factor for the response. The only histological type which is sensitive to immunotherapy is clear cell RCC. Granular, papillary or sarcomatoid type variants are resistant to immunotherapy. The main mechanism of cytokines is still contraversial. Cytokines are binding to specific receptors on tumor cells and initiate intracellular and intercellular signal mechanism. IL-2 is a potent stimulator of T cell proliferation. Anti-tumor T cells rapidly begin to proliferation, then tumor-specific cytotoxic T lymphocytes=CTL, natural killer lymphocytes=NK and probably intratumoral lymphocytes=TIL become active and try to kill tumor cell. However, interferons have some antiangiogenetic effects. Absence of anemia and hypocalcaemia, normal lactic dehydrogenase, prior nephrectomy and good performance status increase possibility of positive response.

The main expectations for immunotherapy in metastatic RCC


Current immunotheraupeutic cytokines are;


#### **4.3 Interferon**

364 Emerging Research and Treatments in Renal Cell Carcinoma

patients, complete and incomplete metastasis resection can provide 44% vs 14% 5-years

In conclusion, the presence of solitary metastases and localization are important factors for clinical improvement. Resection of solitary metastases is recommended for survival and also

Standard cytotoxic drugs are generally ineffective. Response rates were reported below 10%. Response rate was reported 17% with Gemcitabine and 5-Florourasil combination in phase II study. Gemcitabine and capecitabine combination is effective as 20%. But grade 3-4 toxicity was reported. Same regimen reported by CALGB, Survival was 12% and stable disease rate was 59% in this study. Nevertheless toxicity was always a problem. 36% of patients could not continue the treatment protocol. The main problem is neutropenie and

Standard theurepathic regimen is still lack in the management of metastatic RCC. But interferon and interleukin therapy is in management list in many centers. Histological type is the most important factor for the response. The only histological type which is sensitive to immunotherapy is clear cell RCC. Granular, papillary or sarcomatoid type variants are resistant to immunotherapy. The main mechanism of cytokines is still contraversial. Cytokines are binding to specific receptors on tumor cells and initiate intracellular and intercellular signal mechanism. IL-2 is a potent stimulator of T cell proliferation. Anti-tumor T cells rapidly begin to proliferation, then tumor-specific cytotoxic T lymphocytes=CTL, natural killer lymphocytes=NK and probably intratumoral lymphocytes=TIL become active and try to kill tumor cell. However, interferons have some antiangiogenetic effects. Absence of anemia and hypocalcaemia, normal lactic dehydrogenase, prior nephrectomy and good performance status increase possibility of

Overhelming of T-lymphocite dysfunction, dendrtic cell dysfunction, soluble inhibitory

The changes of T-lymphocite antigen receptors and transmission of signals (TCRdelta,

hand-food syndrome. Therefore, phase III studies can not be conducted.

The main expectations for immunotherapy in metastatic RCC

decreasing p56 levels, NFkappaB compliment changes)

factors secreted from tumor cells (IL-10),

 Identification of unique tumor surface antigens Vaccination manuplations for immun tolerence

Current immunotheraupeutic cytokines are;

 Colony-stimulating factors (CSF) Tumor necrosis factor (TNF)

survival advantage (22).

**4. Systemic treatments** 

**4.1 Cytotoxic drugs** 

**4.2 Immunotherapy** 

positive response.

 Interferons İnterleukins

quality of life.

IFN-alpha is approved for the management of metastatic RCC in Europe and it is used routinely in Urological practise. Response rates are 10-25%. Recently, with recombinant forms response rates are increased to 29%. Survival advantage is 3-5 months. Toxicities are flu-like syndromes, dryness in skin and mucosal membranes, mental changes and depression. Combination with IL-2 is frequently applied in many centers. Dosage scheme is controversial.

IFN-beta and gamma are ineffective.

#### **4.4 Interleukin-2 (IL-2)**

A group of cytocine which are activated and regulated lymphocite growing and/ or differantiation

First described one is IL-2.

It is produced by activated CD4+ lymphocites.Cytotoxic T cells are stimulated by IL-2. CD8+ T cells, monocytes, lymphocyte activated killer lymphocytes (LAK) are activated and tumor necrosis factor is secreted. It is reported that IL-2 is as effective as 15% in many series. Rekombinant IL-2 (rIL-2)


Recently, there are more than 10 interleukin described other than IL-2 (IL-4; IL-7; IL-12 have been still investigating)

#### **4.5 Cytokine combination therapy**

Class I MHC Ag expression + T-lymphocite activation


Phase 1 and 2 studies showed that response rates were 6-30%. Retrospective series showed that 15% and 20% response rates, but these results are not statistically significant. Nevertheless, mean survival is a little bit meaningful (9.1 vs 13 mos).

#### **4.6 Targeted therapies**

Since more new agents have been produced and limited number of prospective, randomized, placebo-controlled studies have been reported, Therefore, we have evaluated only;


Contemporary Management in Metastatic Renal Cell Carcinoma 367

(30,31). Nevertheless, still prospective, placebo-controlled studies are significantly lacking in describing the most effective treatment modality in the management of metastatic RCC (32).

Cytotoxic chemotherapy and immunotherapy are less effective treatment modalities in the management of metastatic RCC. However, better understanding of promotion of RCC caused newly produced many targeted therapies. Now, it is early to say that newly introduced drugs can solve the problem, but they are encouraging. .Due to SWOG and EORTC studies which are the most reliable studies in the literature, still primary nephrectomy and combination immunotherapy modalities are the only acceptable choice in

[1] Russo P. Renal cell carcinoma: Presentation, staging and surgical treatment. Semin Oncol

[2] Russo P. Partial nephrectomy: The contemporary gold standard operation for T1 renal

[3] Chan DY, Marshall FF. Surgery in advanced and metastatic renal cell carcinoma. Curr

[4] Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417. [5] Russo P. Surgical intervention in patients with metastatic renal cancer: current status of

[6] Walther MM, Yang JC, Pass HI et al. Cytoreductive surgery before high dose IL-2 based therapy in patients with metastatic renal cell carcinoma. J Urol, 1997; 158:1675-78 [7] Rackley R, Novick AC, Klein EA. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma J Urol. 1994; 152:1399-403 [8] Sella A et al Surgery following response to interferon-alpha-based therapy for residual

[9] Freed SZ, Halperin JP, Gordon M. Idioppathic regression of metastases from renal cell

[10] Marcus SG et al. Regression of metastatic renal cell carcinoma after cytoreductive

[11] Mickisch GHJ. Rational selection of a control arm for randomized trials in metastatic

[12] Wagner JR et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma

[13] Bennett RT, Lerner SE, Taub HC. Cytoreductive surgery for stage IV renal cell

[14] Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in

[16] Wood CG. The role of cytoreductive nephrectomy in the management of metastatic

metastasectomy and cytoreductive nephrectomy. Nat Clin Prac Urol 2004; 1(1): 26-30.

patients with good performance status for the treatment of metastatic RCC.

**5. Conclusion** 

**6. References** 

2000; 27: 160-176.

masses. Am J Urol Rev 2004; 2: 214-222.

renal cell carcinoma. J Urol 1993; 149 (1): 19-21.

carcinoma. J Urol 1977; 118 (4): 538-542.

carcinoma J Urol, 1995; 154: 32-4.

advanced RCC. Urology 1998; 51:933-7.

nephrectomy. J Urol 1993; 150 (2): 463-466.

renal cell carcinoma. Eur Urol 2003; 43: 670-9.

with the kidney in place. J Urol 1999; 162 (1): 43-45.

[15] Finelli A, Kaouk JH, Fergany AF et al. BJU International 2004; 94(3): 291-4.

renal cell carcinoma. Urol Clin N Am 2003; 30:581-588.

Opin Urol 1998; 8(5): 369-373.

#### 4. Temsirolimus (Torisel®) in this review

Sorafenib and/or sunitinib, a multikinase inhibitor of tumor-cell prolferation and angiogenesis, have been shown some activity, in two double blind, placebo-controlled trial in patients with metastatic renal cell ca. All the patients' histology were clear cell ca (24,25). Renal cell carcinoma is most aggressive and mortal genitourinary cancer with more than 40% of patients dying of cancer (26). Unfortunately, no reliable treatment alternative has been still conducted for especially metastatic RCC. Recently, investigations in targeted therapy including multikinase inhibition and antiangioenesis encouraged the clinicans that they have some activity in the management of metastatic RCC. Survival benefit with the targeted therapy was demonstrated in two double blind, placebo-controlled study in the treatment of metastatic disease (24,25). Nevertheless, there are still many unresponded questions. Response rate in different histological type is not clear. We have administered sorafenib in a patient with metastatic RCC with sarcomatoid differentiation and obtained excellent result.

This case report might be an evidence that antiangiogenic agents can be used in any histologic type of renal cell carcinoma.

Additional data on the durability of the response may further clarify the complete response and survival benefit

Inactive VHL gene

#### Fig. 2. Loss of VHL gene and pathways

Small molecule inhibitors have mainly targeted growth factor signals, cell cycle regulatory factors and angiogenesis. Growth factors like VGEF and PDGF have been effective by transmembrane tyrzin kinase receptors which expressed in endothelial cells. They have triggered autophosphorilazition of intracellular tyrozin kinase receptors and protein activation link with the attachment of extracellular parts of receptors. Recently many small molecule inhibitors have been discovered (27,28,29). Raf kinase inhibitors like sorafenib and sunitinib, multiple kinase like VEGFR-2, VEGFR-3 and PDGFR inhibitors or mTOR inhibitors like temsirolimus, everolimus and epidermal growth factor receptor tyrosine kinase inhibitors like erlotinib and lapatinib are the most popular molecules nowadays (30,31). Nevertheless, still prospective, placebo-controlled studies are significantly lacking in describing the most effective treatment modality in the management of metastatic RCC (32).

#### **5. Conclusion**

366 Emerging Research and Treatments in Renal Cell Carcinoma

Sorafenib and/or sunitinib, a multikinase inhibitor of tumor-cell prolferation and angiogenesis, have been shown some activity, in two double blind, placebo-controlled trial in patients with metastatic renal cell ca. All the patients' histology were clear cell ca (24,25). Renal cell carcinoma is most aggressive and mortal genitourinary cancer with more than 40% of patients dying of cancer (26). Unfortunately, no reliable treatment alternative has been still conducted for especially metastatic RCC. Recently, investigations in targeted therapy including multikinase inhibition and antiangioenesis encouraged the clinicans that they have some activity in the management of metastatic RCC. Survival benefit with the targeted therapy was demonstrated in two double blind, placebo-controlled study in the treatment of metastatic disease (24,25). Nevertheless, there are still many unresponded questions. Response rate in different histological type is not clear. We have administered sorafenib in a patient with metastatic RCC with sarcomatoid differentiation and obtained

This case report might be an evidence that antiangiogenic agents can be used in any

Additional data on the durability of the response may further clarify the complete response

Small molecule inhibitors have mainly targeted growth factor signals, cell cycle regulatory factors and angiogenesis. Growth factors like VGEF and PDGF have been effective by transmembrane tyrzin kinase receptors which expressed in endothelial cells. They have triggered autophosphorilazition of intracellular tyrozin kinase receptors and protein activation link with the attachment of extracellular parts of receptors. Recently many small molecule inhibitors have been discovered (27,28,29). Raf kinase inhibitors like sorafenib and sunitinib, multiple kinase like VEGFR-2, VEGFR-3 and PDGFR inhibitors or mTOR inhibitors like temsirolimus, everolimus and epidermal growth factor receptor tyrosine kinase inhibitors like erlotinib and lapatinib are the most popular molecules nowadays

4. Temsirolimus (Torisel®) in this review

histologic type of renal cell carcinoma.

↓

↓

↓

Fig. 2. Loss of VHL gene and pathways

Inactive VHL gene

HIF-1-alfa↑

HIF-alpha/HIF-beta complex ↑

 Hypoxia induced gene transcription ↓ ↓ ↓ ↓

VGEF↑ PDGF-beta↑ TGF-alpha↑ Erythropoietin ↑

excellent result.

and survival benefit

Cytotoxic chemotherapy and immunotherapy are less effective treatment modalities in the management of metastatic RCC. However, better understanding of promotion of RCC caused newly produced many targeted therapies. Now, it is early to say that newly introduced drugs can solve the problem, but they are encouraging. .Due to SWOG and EORTC studies which are the most reliable studies in the literature, still primary nephrectomy and combination immunotherapy modalities are the only acceptable choice in patients with good performance status for the treatment of metastatic RCC.

#### **6. References**


**18** 

*Australia* 

**New Systemic Approaches in the Treatment of** 

Cancer of the kidney comprises approximately 3% of all cancers in males and 2% in females according to Cancer Research UK statistics. (http://info.cancerresearchuk.org) Similar figures are seen globally. The majority (around 90%) of kidney cancers are Renal Cell Carcinomas (RCC), and clear cell carcinomas (adenocarcinomas) are the most common histological subtype. (Cohen & McGovern, 2005) The remaining 20-25% are papillary (Type I and II) (10-15%), chromophobe (4%) and collecting duct (including the rare medullary variant) (<1%) RCCs. (Cohen & McGovern, 2005) Up to a third of patients present at initial diagnosis with evidence of distant metastases, and a third of patients who undergo nephrectomy will have a recurrence within 5 years. These patients are considered

Unravelling of the biology, genetics and intracellular molecular signalling pathways of RCC has greatly improved our understanding of this disease. (Tan *et al*, 2010) The discovery of von Hippel-Lindau (VHL) tumour suppressor gene as a critical oncogene in the pathogenesis of renal cell carcinoma (clear-cell as well as some of the non-clear-cell variant) has greatly revolutionised the systemic therapy for renal-cell carcinoma where previously treatment had been disheartening. (Choueiri *et al*, 2008; Cohen & McGovern, 2005) The VHL protein (pVHL) encoded by the VHL tumour suppressor gene serves to regulate the normal cellular response to oxygen deprivation through its interaction with hypoxia-inducible factor (HIF). HIF is a heterodimeric (HIF-α/β) gene transcription factor that consists of an unstable α-subunit and a stable β-subunit. In the presence of normal oxygen tension (or normoxic state), VHL protein is the substrate recognition of an E3 ubiquitin ligase complex that targets HIF-α subunits for destruction by the proteasome as illustrated in Figure 1. (Kamura et al, 2000; Ohh et al, 2000) In the absence of functional VHL proteins, either as a result of mutation or hyper-methylation of the VHL gene as seen in majority of sporadic

candidates for systemic therapy. (Molina & Motzer, 2008)

**2. Molecular pathogenesis** 

**2.1 Clear-cell variant renal cell carcinoma** 

**1. Introduction** 

**Metastatic Renal Cell Carcinoma** 

Ganesalingam Pranavan2 and Desmond Yip2,3

*1RAH Cancer Centre, Royal Adelaide Hospital, 2Medical Oncology Unit, The Canberra Hospital, 3ANU Medical School, Australian National University,* 

Thean Hsiang Tan1, Judith Lees1,

